Agilent Technologies

Delaware BioScience Association announces new president

Monday, November 21, 2016

The Delaware BioScience Association (Delaware Bio) has announced that its founding President Bob Dayton is retiring after 10 years of achieving continuous growth and increasing influence. As of February 1, Dayton will be succeeded by Helen Stimson, who will leave her current role as vice president and general manager of the Chemistries and Supplies Division at Agilent Technologies at the end of the month.

[Read More]

Agilent Technologies receives expanded FDA approval to inform treatment in non-small cell lung cancer (NSCLC)

Thursday, October 27, 2016

Agilent Technologies Inc. announced that its Dako PD-L1 IHC 22C3 pharmDx now has an expanded label approved by the U.S. Food and Drug Administration (FDA) for use in determining PD-L1 expression status to inform treatment in metastatic non-small cell lung cancer (NSCLC) with KEYTRUDA® (pembrolizumab). This expanded intended use now allows the PD-L1 IHC 22C3 pharmDx test to detect PD-L1 expression in a broader range of patients–those with a PD-L1 tumor proportion score (TPS) of 1 percent or more.

[Read More]

Agilent, Weill Cornell collaborate on ALS

Thursday, August 27, 2015

Agilent Technologies is collaborating with Dr. Steven Gross, a faculty member in the department of pharmacology at Weill Cornell Medical College in New York, to advance research in amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease. Agilent will provide the latest mass spectrometry technology to support his research, working toward an understanding of how the most common form of the disease develops in the body.

[Read More]

Dako, Ono Pharmaceutical to collaborate on diagnostic test Opdivo

Wednesday, February 18, 2015

Dako, an Agilent Technologies company and a worldwide provider of cancer diagnostics, and Ono Pharmaceutical, headquartered in Osaka, Japan, have partnered to develop a potential diagnostic test specifically for use with Opdivo in the treatment of non-small cell lung cancer. This test is being investigated for its diagnostic utility to determine which patients are most likely to respond to Opdivo.

[Read More]